The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

Arthritis & Rheumatology
Dinesh KhannaDaniel E Furst

Abstract

Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs). We developed 150 paper patient profiles with standardized clinical outcome elements (core set items) using patients with dcSSc. Forty scleroderma experts rated 20 patient profiles each and assessed whether each patient had improved or not improved over a period of 1 year. Using the profiles for which raters had reached a consensus on whether the patients were improved versus not improved (79% of the profiles examined), we fit logistic regression models in which the binary outcome referred to whether the patient was improved or not, and the changes in the core set items from baseline to followup were entered as covariates. We tested the final index in a previously completed RCT. Sixteen of 31 core items were included in the patient profiles after a consensus meeting and review of test characteristics of patient-level data. In the logistic regression model in which the included core set items were change over 1 year in the modified Rodnan skin thickness score, the forced vital capa...Continue Reading

References

Feb 1, 1992·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·R D Hays, D Hadorn
Feb 1, 1992·Annals of the Rheumatic Diseases·D M van der HeijdeL B van de Putte
Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Jul 1, 1997·Arthritis and Rheumatism·E H GianniniA Martini
Nov 18, 2000·Arthritis and Rheumatism·V D Steen, T A Medsger
Oct 2, 2002·Arthritis and Rheumatism·Peter A MerkelUNKNOWN Scleroderma Clinical Trials Consortium
Jan 11, 2005·The American Journal of Medicine·John P A IoannidisHaralampos M Moutsopoulos
Sep 20, 2005·Trends in Immunology·David J Abraham, John Varga
Jun 2, 2006·Arthritis and Rheumatism·Jasvinder A SinghUNKNOWN Classification and Response Criteria Subcommittee of the Committee on Quality Measures, American College of Rheumatology
Jun 23, 2006·The New England Journal of Medicine·Donald P TashkinUNKNOWN Scleroderma Lung Study Research Group
May 16, 2007·Current Rheumatology Reports·Dinesh Khanna, Peter A Merkel
Sep 19, 2007·Journal of Inherited Metabolic Disease·E H DaviesA Vellodi
Sep 26, 2007·Annals of the Rheumatic Diseases·D KhannaUNKNOWN Scleroderma Clinical Trials Consortium co-authors
Apr 29, 2008·Arthritis and Rheumatism·Peter A MerkelUNKNOWN Scleroderma Clinical Trials Consortium
Apr 1, 2009·Arthritis and Rheumatism·Dinesh KhannaUNKNOWN Relaxin Investigators and the Scleroderma Clinical Trials Consortium
Aug 1, 2009·Arthritis and Rheumatism·Sogol AmjadiUNKNOWN Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials
Mar 23, 2011·Seminars in Arthritis and Rheumatism·Raj NairDinesh Khanna
Dec 21, 2013·Journal of the American College of Cardiology·Marius M HoeperDavid B Badesch
Jul 30, 2014·Rheumatology·Vivek NagarajaDinesh Khanna

❮ Previous
Next ❯

Citations

May 6, 2016·Current Rheumatology Reports·Jessica K Gordon, Robyn T Domsic
Apr 18, 2017·Lancet·Christopher P Denton, Dinesh Khanna
Oct 11, 2017·Rheumatology·Gábor KumánovicsLászló Czirják
Mar 27, 2018·Arthritis Care & Research·Sindhu R Johnson, Peter C Grayson
Aug 17, 2018·Nature Reviews. Rheumatology·Christopher P DentonJohn G Coghlan
Sep 21, 2018·Current Opinion in Rheumatology·Flavia V Castelino, Paul F Dellaripa
Dec 19, 2018·Modern Rheumatology·Yoshihito Shima
Apr 1, 2019·Annals of the Rheumatic Diseases·Nava FerdowsiUNKNOWN Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Sclero
Oct 31, 2019·Annals of the Rheumatic Diseases·Kevin L WinthropDaniel Furst
Mar 18, 2020·Expert Opinion on Investigational Drugs·Melody P Chung, Lorinda Chung
Jun 23, 2019·Annals of the Rheumatic Diseases·Mike BeckerUNKNOWN EUSTAR Collaborators (numerical order of centres)
May 6, 2020·Arthritis & Rheumatology·Monique Hinchcliff
Jul 18, 2020·Expert Opinion on Pharmacotherapy·Zsuzsanna H McMahan, Elizabeth R Volkmann
Sep 8, 2020·Expert Review of Clinical Immunology·Vasiliki LiakouliRoberto Giacomelli
May 26, 2016·Annals of the Rheumatic Diseases·Janet E Pope
Aug 20, 2019·Arthritis Care & Research·Laura RossMandana Nikpour
Nov 21, 2018·Frontiers in Immunology·Alexandre T J MariaPhilippe Guilpain
Mar 25, 2019·Journal of Scleroderma and Related Disorders·Murray BaronAlessandra Vacca
May 24, 2018·Nature Reviews. Rheumatology·Peter J WermuthSergio A Jimenez
Jun 5, 2020·Arthritis Research & Therapy·Bettina MüllerOliver Distler
Jun 7, 2020·Arthritis Research & Therapy·Boyang ZhengUNKNOWN Canadian Scleroderma Research Group
Oct 23, 2020·Arthritis Care & Research·Ting Yi Jessica Chang, Janet E Pope
Oct 16, 2020·Expert Opinion on Emerging Drugs·David RoofehDinesh Khanna
Sep 1, 2020·The Lancet. Respiratory Medicine·Dinesh KhannaUNKNOWN focuSSced investigators
Jun 11, 2021·Bone Marrow Transplantation·Nassim Ait AbdallahDominique Farge
Jul 29, 2021·Journal of Scleroderma and Related Disorders·Alain LescoatDinesh Khanna
Aug 12, 2021·Indian Journal of Dermatology, Venereology and Leprology·Anza KhaderNeeraj Manikath
Aug 27, 2021·Expert Opinion on Drug Safety·Esther F Vicente-RabanedaSantos Castañeda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.